Skip to content

Upstream Bio, Inc. UPB Shares (Diluted)

Shares (Diluted) at other companies

Amgen logo
AmgenAMGN
544M+0.6%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
107.7M-3.1%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
128.8M+5.2%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
112.2M+120%
Savara logo
SavaraSVRA
253.3M+17.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
28.7M-6.4%

Other financials

Income statement

See full
Revenue$1.0M+82.7%
Operating income-$43.6M-36.2%
Net income-$40.6M-48.8%
EPS (diluted)-$0.75-47.1%

Balance sheet

See full
Cash & equivalents$96.7M+35.6%
Total debt$1.1M-34.5%
Total equity$304.0M-31.8%
Total assets$318.1M-30.3%

Cash flow

See full
Operating cash flow-$47.9M-16.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$346.11M-40.9%
Enterprise value$250.5M-51.4%
P/S104.2×-151×

Profitability

See full
Operating margin-5,176.5%+1,764pp
Net margin-4,719%+2,752pp

Returns & leverage

See full
Return on equity-41.8%
Debt / equity0.0×
Current ratio23.1×-24.3×

Where this comes from

Reported directly by Upstream Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: Upstream Bio, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Upstream Bio, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Upstream Bio, Inc.'s shares (diluted)?
Upstream Bio, Inc. (UPB) reported shares (diluted) of 54.3M in Q1 2026.
How has Upstream Bio, Inc.'s shares (diluted) changed year-over-year?
Upstream Bio, Inc.'s shares (diluted) increased by 1.3% year-over-year, from 53.6M to 54.3M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.